Introduction {#s0005}
============

Hypoxia contributes to aggressiveness, resistance to treatment, and metastatic dissemination of cancer [@bb0005], [@bb0010], [@bb0015], [@bb0020]. Prostate cancer (PCa) ranks high among the malignancies in which hypoxia plays a major role in treatment resistance and metastases [@bb0025], [@bb0030]. In PCa, hypoxia associated gene expression of lysyl oxidase and glucose transporter-1 (GLUT-1) has been correlated with Gleason score [@bb0035]. More recently, carbonic anhydrase (CA) IX, another hypoxia regulated enzyme that plays a role in cytoplasmic pH regulation of cancer cells, was found to correlate with higher Gleason scores [@bb0040]. Hypoxia has also been implicated in the emergence of castration-resistant PCa cells [@bb0045]. In a large clinical study, PCa hypoxia was associated with early biochemical relapse after radiotherapy and with local recurrence [@bb0050]. In a separate retrospective analysis of two randomized radiotherapy trials and one surgical cohort study, increased staining of HIF-1α was a significant predictor of biochemical failure after radiotherapy or surgery [@bb0055]. In preclinical studies, prostate cancer models such as those developed from the Dunning prostate cancer model [@bb0060] at Johns Hopkins, [@bb0065] have been well characterized in terms of differences in patterns of vascularization, hypoxia, and radiation response [@bb0070], [@bb0075], [@bb0080].

Chronic hypoxia results from the limited diffusion of oxygen to tumor cells distant from blood vessels [@bb0085]. Acute hypoxia can result from vascular collapse due to increased tumor interstitial pressure [@bb0085]. The formation of hypoxia results in the upregulation of vascular endothelial growth factor [@bb0090] that can lead to increased angiogenesis and neovascularization and reoxygenation of hypoxic regions. Reoxygenation also occurs during therapy, or during tumor evolution, when cell death provides increased nutrients and oxygen to the remaining cells [@bb0070], [@bb0095], [@bb0100], [@bb0105].

The adaptive response of cancer cells to hypoxia is mediated through the stabilization of hypoxia inducible factors (HIFs) that increases the transcription of several genes mediating this response by binding to hypoxia response elements (HREs) in the promoter region of these genes [@bb0025]. HIF is a heterodimeric basic helix-loop-helix PAS (Per-ARNT-Sim) domain containing transcription factor that consists of one of three oxygen-regulated α-subunits, HIF-1α, HIF-2α, and HIF-3α and a constitutively expressed β-subunit (HIF-β/ARNT) [@bb0110], [@bb0115]. The α-subunits are constitutively transcribed and translated but are regulated at the protein level by oxygen-dependent hydroxylation of specific prolyl residues and degraded due to the presence of an oxygen-dependent degradation domain (ODD) [@bb0120].

There is a critical need to understand the metastatic cascade in PCa to design effective interventions to prevent metastasis and to identify markers of aggressiveness. We developed an HRE-driven imaging strategy that combines the hypoxia-driven expression of two optical reporters with different half-lives to detect temporal changes in hypoxia and HIF activity [@bb0125]. For this purpose, human PCa cells were transfected with the luciferase (luc) gene fused with an oxygen-dependent degradation domain (ODD-luc) and a variant of the enhanced green fluorescent protein (EGFP), both of which were driven by a five--tandem repeat HRE sequence (5xHRE). The cells constitutively expressed tdTomato red fluorescent protein (RFP) that was regulated by a phosphoglycerate kinase (pGK) promoter. This novel "timer" imaging strategy of combining the short-lived ODD-luc and the long-lived EGFP, provided a time frame of HRE activation in tumors derived from these PCa cells that was used, for the first time, to understand the relationship between temporal changes in hypoxia in primary and metastatic lesions. Since human cancer xenografts metastasize more readily from the orthotopic implantation site compared to a subcutaneous inoculation site [@bb0010], [@bb0130], [@bb0135], PC-3-HRE-EGFP/HRE-ODD-luc/tdTomato cells were inoculated subcutaneously or orthotopically in a group of mice to determine if differences in expression patterns of luc and EGFP were detected in primary tumors and metastatic lesions. By using this novel timer-reporter strategy, we characterized hypoxia patterns in human PCa xenografts and metastatic lesions that developed in tumor-bearing mice. With this timer strategy, regions with high bioluminescence (BL) but low EGFP may represent early or acute hypoxia, regions with high BL and high EGFP may represent long-term chronic hypoxia, and regions with low BL and high EGFP may represent reoxygenated regions that were previously hypoxic [@bb0125]. We detected significant differences in the patterns of expression of the timer-reporters between subcutaneous and orthotopic tumors and in the metastatic lesions that provide new insights into the development of hypoxia and its role in metastatic dissemination from these tumors.

Materials and Methods {#s0010}
=====================

Generation of PC3-HRE-EGFP/HRE-ODD-luc Cells {#s0015}
--------------------------------------------

Detailed methods and validation of the system were previously reported [@bb0125]. Briefly, to construct the plasmid encoding the luc gene fused to ODD under the regulation of a five--tandem repeat of HRE sequence (5xHRE) with a puromycin resistance cassette, the *5xHRE-ODD-luc* (firefly luciferase fused with ODD) sequence from a 5HREp-ODD-luc plasmid (kindly provided by Dr. H. Harada) was digested with KpnI and XbaI and subcloned between KpnI and EcoRI of a pGL4.21\[luc2P/Puro\] vector (Promega, Madison, WI). Human PCa PC-3 cells expressing EGFP variant pd2EGFP under the promotion of a 5xHRE sequence (PC3-HRE-EGFP) were transfected with the 5xHRE-ODD-luc construct (PC3-HRE-ODD-luc and PC3-HRE-EGFP/HRE-ODD-luc) using jetPRIME reagent (Polyplus transfection) following the manufacturer\'s protocol. Transfected cells were selected using 1 μg/ml of puromycin. PC3-HRE-EGFP/HRE-ODD-luc cells constitutively expressing the bright red fluorescent protein tdTomato (PC3-HRE-EGFP/HRE-ODD-luc/tdTomato) were generated by lentiviral infection with the pRRL-Δluc-tdtomato plasmid [@bb0125].

Cell Inoculation and Animal Studies {#s0020}
-----------------------------------

All experimental animal protocols and animal handling were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University School of Medicine and conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. Male adult nude mice were inoculated subcutaneously with 2×10^6^ cancer cells. For orthotopic implantation, a 1-mm^3^ piece of tumor tissue obtained from a subcutaneous tumor was microsurgically sutured into the prostate gland through a small incision as previously described [@bb0135]. Tumor pieces used for implantation were carefully dissected under a fluorescence microscope to remove hypoxic and necrotic tissue. Subcutaneous (*n* = 3) and orthotopic (*n* = 5) tumor volumes, measured *ex vivo*, were approximately 450± 94 mm^3^ and 720± 151 mm^3^ \[mean ± standard error of the mean (SEM)\] respectively, at the time of imaging. There was no close association between tumor volume and metastatic dissemination.

*In Vivo* Optical Imaging {#s0025}
-------------------------

Optical imaging was performed using an IVIS Spectrum scanner (Caliper Life Sciences, Hopkinton, MA). EGFP was detected using an excitation light of 500 nm and an emission filter set at 540 nm. tdTomato was detected using an excitation light of 570 nm and an emission filter set at 620 nm as described earlier [@bb0125]. To detect the expression of luc *in vivo* with bioluminescent imaging (BLI), 100 μl of a 30 mg/ml solution of D-luciferin (Promega, P1042, VivoGlo Luciferin, *In Vivo* Grade, potassium salt) dissolved in PBS was injected intraperitoneally (\~3 mg/mouse) 15 minutes prior to imaging. We used an exposure time of 1 second for GFP and tdTomato and 1 minute for BLI, with a 6.4×6.4-cm field of view.

*Ex Vivo* Optical Imaging {#s0030}
-------------------------

Endpoint optical imaging of fluorescence and BL of fresh 2-mm--thick tumor slices, prepared with a tissue slicer, was performed with the IVIS Spectrum scanner. To quantify fluorescence and BL in tissue slices, 2-mm--thick tumor slices, obtained from the tumor after euthanization of mice following *in vivo* imaging, were imaged. We used an exposure time of 0.1-0.2 second for EGFP and tdTomato and 30 second-1 minute for BLI. The *ex vivo* image analyses were done on normalized images using the IVIS software.

Fluorescence and BL areas higher than 50% of the background were determined in the tumor slices using the Living Image software (Perkin Elmer, Waltham, MA) and normalized to the total area of each slice to obtain fractional areas of EGFP and BL.

Statistical Analyses {#s0035}
--------------------

All results are represented as mean ± SEM. Comparisons between groups were performed using a two-tailed unpaired Student\'s *t* test. *P* values \< .05 were considered to be statistically significant unless otherwise stated.

Results {#s0040}
=======

Orthotopic tumors formed detectable metastatic lesions frequently, unlike the subcutaneous tumors (three of five mice with orthotopic tumors displayed metastasis, whereas none of the mice with subcutaneous tumors had detectable metastasis). Representative *in vivo* optical images of an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor with a peritoneal metastatic lesion revealing patterns of luc and EGFP expression in primary and metastatic lesions are shown in [Figure 1](#f0005){ref-type="fig"}, *A*-*C*. Optical images from (A) tdTomato expression that identifies cancer cells, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression are displayed. The EGFP fluorescence and luc BL distributions demonstrate patterns of chronic and acute hypoxia in the primary and metastatic lesions. Here, the primary tumor had a small focus of EGFP expression indicative of long-term exposure to hypoxia that was also identified with BLI but within a smaller area, suggesting that the hypoxia may have been resolving. In contrast, there were areas of BL in the primary tumor and in the metastatic lesion that were not detected in the EGFP image that suggested that these regions were newly hypoxic.Figure 1Representative *in vivo* optical images of an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor-bearing mouse with a peritoneal metastatic lesion revealing patterns of EGFP and BL expression in primary and metastatic lesions. Optical images are from (A) tdTomato expression to identify cancer cells, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression. Scale bar: 0.5 cm.Figure 1

We also observed examples of tumors where only BL was observed but not EGFP fluorescence, as shown in the representative examples of tdTomato, EGFP, and luc expression in [Figure 2](#f0010){ref-type="fig"}, *A*-*C* where, in this instance, hypoxia must have occurred within an 8-hour time frame that allowed expression of luc but not EGFP. In this mouse, we also observed a metastatic lesion expressing EGFP but not luc. The difference in BL intensities between [Figures 1](#f0005){ref-type="fig"}*C* and [2](#f0010){ref-type="fig"}*C* was most likely because of differences in the amount of luciferin reaching the tumor.Figure 2Representative *in vivo* optical images of an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor-bearing mouse with extensive BL but no EGFP expression. Also observed is a small metastatic lesion that expresses EGFP fluorescence but not BL. Optical images are from (A) tdTomato expression to identify cancer cells, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression. Scale bar: 0.5 cm.Figure 2

Representative *ex vivo* images of a metastatic nodule in the liver formed from an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor are displayed in [Figure 3](#f0015){ref-type="fig"}, *A*-*C*. Optical images from (A) tdTomato expression to identify cancer cells, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression are displayed. In this metastatic nodule, fluorescence from EGFP and BL from luc is observed in two distinct regions of the lesion identified by RFP expression. The EGFP fluorescing area without BL suggests that cells in this region were previously exposed to hypoxia, whereas the BL region without EGFP expression suggests that hypoxia must have occurred within the past 8 hours that allowed luc to be formed but not EFGP.Figure 3Representative *ex vivo* images of a metastatic nodule in the liver resulting from an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor. Optical images are from (A) tdTomato expression to identify cancer cells, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression. In this metastatic nodule, the EGFP fluorescence and BL are observed in two distinct regions of the tumor. Scale bar: 0.5 cm.Figure 3

In [Figure 4](#f0020){ref-type="fig"}, *ex vivo* images of (A) tdTomato expression, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression in eight metastatic lesions obtained from a single mouse (Met 1 to Met 8) with an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor are displayed together with (D) bar plots of the fractional area of EGFP and luc expression in these lesions. There is an overall trend towards higher EGFP and lower BL fractional areas in these metastatic lesions, suggesting that cancer cells in the metastatic lesions were exposed to hypoxia within the past 8-24 hours either at the primary site or at the metastatic site but were not hypoxic in the metastatic lesion when imaged.Figure 4*Ex vivo* images of (A) tdTomato expression, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression in eight metastatic lesions (Met 1 to Met 8), obtained from a single mouse with an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor, are displayed together with (D) bar plots of the fractional area of EGFP fluorescence and BL in these lesions. Scale bar: 0.5 cm.Figure 4

Representative images of tdTomato, EGFP, and luc expression from cancer cells in ascites fluid, obtained from the peritoneal cavity of a mouse with an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor, are shown in [Figure 5](#f0025){ref-type="fig"}, *A*-*C*. Cancer cells in the ascites fluid expressed EGFP but not luc, suggesting that these cells were exposed to hypoxia within the past 8-24 hours but were not hypoxic when imaged.Figure 5Representative images of cancer cells in ascites fluid obtained from the peritoneal cavity of a mouse with an orthotopic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato tumor. Optical images are from (A) tdTomato expression to identify cancer cells, (B) HRE-driven EGFP expression, and (C) HRE-driven luc expression. Scale bar: 0.5 cm.Figure 5

Patterns of EGFP and BL obtained from *ex vivo* subcutaneous and orthotopic tumors, and *ex vivo* metastatic nodules are shown in [Figure 6](#f0030){ref-type="fig"}. Fractional areas of EGFP or BL were not significantly different between subcutaneous and orthotopic tumors. However, fractional areas of EGFP were significantly higher and fractional areas of BL were significantly lower in the metastatic lesions compared to subcutaneous and orthotopic tumors. These results suggest that cells in metastatic lesions had been previously exposed to hypoxia, either at the primary tumor site or at the metastatic site, but the hypoxia had resolved. Within each group, the EGFP fractional area was significantly higher than the BL area in orthotopic tumors and metastatic lesions but not in subcutaneous tumors.Figure 6Bar plot displaying fractional areas of EGFP and luc expression in subcutaneous and orthotopic tumors and in metastatic nodules. Significantly higher fractional areas of EGFP fluorescence and significantly lower fractional areas of BL area were observed in metastatic lesions compared to primary tumors, suggesting that cells in metastatic lesions had been previously exposed to hypoxia either at the primary tumor site or at the metastatic site but the hypoxia had resolved. Within the groups, orthotopic tumors and metastatic lesions had significantly higher EGFP fluorescing areas compared to BL areas. Values represent mean +/- SEM from subcutaneous tumors (*n* = 3), orthotopic tumors (*n* = 5), and 15 metastatic nodules obtained from 3 orthotopic mice (*n* = 3). \*Two-tailed *t* test, \#1-tailed *t* test, *P* \< .05.Figure 6

Since BL depends on HRE-driven luc expression as well as the delivery of D-luciferin to the tumor, a PC3-HRE-EGFP/HRE-ODD-luc tumor was imaged *ex vivo* immediately after *in vivo* imaging and reimaged after layering D-luciferin solution directly on the tumor slice. As shown in [Supplementary Figure S1](#ec0005){ref-type="supplementary-material"}, layering D-luciferin on the tumor slice increased the BL signal intensity but did not reveal any additional BL areas, indicating effective delivery of D-luciferin within the tumor and the hypoxia dependence of BL.

Discussion {#s0045}
==========

Our purpose in this study was to characterize hypoxic environments in primary and metastatic lesions to gain further insights into the role of hypoxia in the metastatic cascade. We used a timer strategy based on the combination of two reporter genes, regulated by an HIF-dependent promoter, with different degradation half-lives. We previously established that EGFP has a degradation half-life of approximately 15 hours, while ODD-luc has an approximate half-life of 34 minutes [@bb0125]. We also previously established that luc significantly increased within 4 hours of exposure to 1% O~2~, whereas EFGP significantly increased between 8 and 24 hours of exposure to 1% O~2~ [@bb0125]. The combination of a long-lived EGFP and a short-lived luciferase fused to ODD allowed the identification of normoxic (EGFP−/luc−), hypoxic (EGFP+/luc+ or EGFP−/luc+), and reoxygenated (EGFP+/luc−) tumor microenvironments. Patterns of expression of the two reporters allowed us, for the first time, to evaluate hypoxia within the primary and metastatic sites of these xenografts.

We identified all four patterns of EFGP and luc expression in the primary and metastatic tumors. When we characterized the fractional area of EFGP and luc expression, we did not detect significant differences between subcutaneous and orthotopic tumors even though orthotopic PC-3 tumors are more metastatic than subcutaneous PC-3 tumors [@bb0010], [@bb0130], [@bb0135]. This is similar to our previous observations where we did not detect significant differences in HRE-driven EGFP expression between subcutaneous and orthotopic tumors, suggesting that hypoxia alone did not drive metastasis [@bb0130]. We have previously found that denser collagen 1 fibers and increased numbers of cancer associated fibroblasts are closely associated with a PCa dissemination permissive extracellular matrix [@bb0130]. The fractional area of EGFP expression was, however, significantly higher in the metastatic lesions compared to primary subcutaneous or orthotopic tumors, and the fractional area of luc expression was significantly lower in the metastatic lesions compared to primary subcutaneous or orthotopic tumors. Based on the half-lives of EGFP and luc (15 hours *versus* 34 minutes) and the hypoxia response times of EFGP and luc (8--24 hours *versus* 4 hours), these data suggest that cancer cells in the metastatic site were previously exposed to hypoxia. Since the fractional area of BL was significantly lower at the metastatic site, this suggests that these cancer cells may have been exposed to hypoxia at the primary site but not at the metastatic site.

Hypoxia alone was not sufficient to create a metastasis permissive environment (schematic in [Figure 7](#f0035){ref-type="fig"}*A*) since both chronic and acute hypoxic areas were not significantly different between primary tumor sites that are preventive (subcutaneous) or permissive (orthotopic) for metastasis. However, within groups, EGFP areas were significantly higher compared to BL areas in orthotopic tumors that metastasized as well as in metastatic sites. The significantly higher areas of EGFP compared to BL in orthotopic compared to subcutaneous tumors suggests that reoxygenation and the ability to reoxygenate may contribute to a metastasis permissive environment.Figure 7Schematic display of combinations of EGFP fluorescence and luc BL in primary tumors and metastatic sites and their interpretation. (A) Patterns of EGFP fluorescence and luc BL were comparable between nonmetastatic subcutaneous tumors and metastatic orthotopic tumors, indicating that there were barriers to prevent cells from leaving the primary subcutaneous tumors but these barriers were reduced in the orthotopic site. (B) In metastatic lesions from the orthotopic site, scenario 3 was the most prevalent.Figure 7

In metastatic sites, there was a four-fold difference between EGFP and BL fractional areas, suggesting that a high fraction of cells had been previously exposed to hypoxia. This could have been due to efficient reoxygenation occurring at the metastatic site or reoxygenated cells from the primary site continuing to seed the metastatic site. Repetitive cycles of hypoxia and reoxygenation have been previously observed to increase tumorigenicity in breast cancer cells [@bb0140]. Malignant ascites, although rare, is one complication that arises in advanced PCa from peritoneal metastasis. We found a similar pattern of high EGFP expression, but not luc, in cancer cells detected in ascites fluid, again suggesting that these cells had been exposed to hypoxia but had reoxygenated when shed into the peritoneal cavity.

The results suggest that reoxygenation in the primary tumor may result in a metastasis-permissive environment, as shown in the schematic in [Figure 7](#f0035){ref-type="fig"}*B*. The transcriptional regulation of several genes is modified by HIF, many of which are known to play a role in PCa invasion and metastasis [@bb0145], [@bb0150], once the avenues to metastasize, including the vasculature and a permissive extracellular matrix, are available [@bb0130], [@bb0155]. Hypoxia may also increase detachment of cells from the extracellular matrix [@bb0160] that may have played a role in the patterns observed in malignant ascites.

The limitations of our study were that we could only report on hypoxia through HIF stabilization and were not able to quantify oxygen tensions. Also, fluorescence from EGFP and BL from luc have different depths of attenuation. We therefore excised the lesions and performed imaging on 2-mm slices to quantify differences in fractional areas of EGFP fluorescence and BL. The patterns of reporter expression allowed us to confirm, for the first time, the presence of hypoxia in metastatic as well as primary lesions. While hypoxia is known to play an important role in invasion and metastasis, two critical questions are whether metastatic dissemination occurs from hypoxic primary tumor regions or if distant sites that attract metastatic cancer cells are hypoxic. Our data with this model system suggest that hypoxia followed by reoxygenation may result in a more metastatic phenotype and that hypoxia alone is not sufficient to permit metastasis. Our data support targeting hypoxia to potentially prevent metastatic dissemination from primary tumors. Development of timer proteins that provide better temporal resolution and faster response to stimuli is important to further delineate the role of hypoxia in metastatic dissemination.

The following are the supplementary data related to this article.Supplementary Figure S1Validation of D-luciferin delivery to tumor tissues from peritoneal injection. To validate effective delivery, a PC3-HRE-EGFP/HRE-ODD-luc tumor was imaged *ex vivo* immediately after *in vivo* imaging (Supplementary Figure S1*A* top). D-luciferin solution was subsequently layered on the tumor slice that was reimaged (Supplementary Figure S1*A* bottom). Intensities were adjusted to the same scale. As shown in Supplementary Figure S1*B*, layering D-luciferin on the tumor slice increased the average radiance (dark blue bar compared to light blue bar, left) but did not reveal any increase of fractional area of BL (dark blue bar compared to light blue bar, right), indicating effective delivery of D-luciferin within the tumor and hypoxia dependence of BL. Scale bar: 0.5 cm.Supplementary Figure S1
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